Cloning and Interfering Factors

Banafsheh Heidari¹, Sara Borjian Boroujeni¹, Mahmood Jeddi-Tehrani², Amir Hassan Zarnani^{3,4}, Mohammad Mehdi Akhondi¹, Abolfazl Shirazi^{1,5,*}

1- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

2- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

3- Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

4- Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran

5- Department of Cloning and Stem Cell, Research Institute of Animal Embryo Technology, Shahrekord University, Shahr-e-Kord, Iarn

Abstract

Background: The term "Cloning" has originated from "Klon", a Greek word with the meaning of a small twig that can multiply by itself and turn to a generative tree. Cloning is an asexual reproduction in which a copy or multiple copies of an organism are generated by transferring the nucleus (DNA) of a somatic cell into an enucleated metaphase-II oocyte. Despite the benefits and potentially broad applications of this technology, its low efficiency, especially in the production of viable offspring, has implicated its application with serious challenges. In this article, we will review papers related to its emerging principles, with an emphasis on epigenetic modifications, which appear to govern the efficiency of cloning.

Methods: The literature review was carried out by searching through knowledge-based data bases such as ScienceDirect, PubMed and Scopus on the internet. No time limit was considered for literature review of the relevant articles up to the time of submission.

Results: Considering the large varieties of factors affecting cloning, improvements in cloning efficiency are dependent on the increment of theoretical knowledge and technical expertise of its procedures. This can be achieved by improving oocyte and cytoplasmic maturation, optimizing synchronization between the nucleus of the donor cell and cytoplasm of MII stage oocyte, minimizing the physical insults to the cytoskeleton of oocyte during enucleation and nuclear transfer, improving the cellular fusion and culture conditions of reconstructed oocytes and in particular and more importantly by employing effective methods to qualitatively alter the epigenetic status of the incoming nucleus to an embryonic or totipotent state, leading to the improvement of donor cell reprogramming. Considering the importance of inherited maternal transcripts and proteins in cytoplasm of fully matured oocytes in supporting the embryos up to the embryonic genomic activation (EGA) and the capability of MII stage cytoplasm in dedifferentiating mammalian somatic cells and coincident of EGA with depletion of maternally originated transcripts, reprogramming of the somatic cell nuclei must be completed by the time that the embryonic genome is activated. Since the patterns of epigenetic modification are dynamic and not static during development, the optimum procedure to properly induce nuclear reprogramming should follow the pattern of epigenetic modifications in normal embryo development.

Conclusion: Besides the all progresses in reproductive cloning using highly efficient methods, any deviation from the normal pattern of mRNA expression due to epigenetic changes induced by chemical interventions in early preimplantation embryo may persist throughout fetal development. The effects of these aberrations may manifest later in development. Nonetheless, understanding the kinetics of normal molecular events related to epigenetic modifications and identification of the specific factors present in the ooplasm, which are necessary for epigenetic reprogramming, will provide a better understanding of the underlying mechanisms and would improve cloning efficiency and other related technologies.

Keywords: Cloning, Enucleation, Epigenetic modification, Nuclear reprogramming, Reconstructed oocyte.

To cite this article: Heidari B, Borjian Boroujeni S, Jeddi-Tehrani M, Zarnani AH, Akhondi MA, Shirazi A. Cloning and Interfering Factors. J Reprod Infertil. 2011;12(2):47-72.

* Corresponding Author: Abolfazl Shirazi, Department of Embryology, Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran. *E-mail:* shiraziabbas@yahoo.com

a.shirazi@avicenna.ac.ir

Received: Sept. 30, 2010 **Accepted:** Dec. 22, 2010